Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.
The potential use of the Trypanosoma cruzi metacyclic trypomastigote (MT) stage-specific molecule glycoprotein-82 (gp82) as a vaccine target has not been fully explored. We show that the opsonization of T. cruzi MT with gp82-specific antibody prior to mucosal challenge significantly reduces parasite infectivity. In addition, we investigated the immune responses as well as the systemic and mucosal protective immunity induced by intranasal CpG-adjuvanted gp82 vaccination. Spleen cells from mice immunized with CpG-gp82 proliferated and secreted IFN-γ in a dose-dependent manner in response to in vitro stimulation with gp82 and parasite lysate. More importantly, these CpG-gp82-immunized mice were significantly protected from a biologically relevant oral parasite challenge.
Eickhoff
Christopher S
CS
Departamento de Microbiologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brasil.
Giddings
Olivia K
OK
Yoshida
Nobuko
N
Hoft
Daniel F
DF
D000281:Administration, Intranasal; D000818:Animals; D014355:Chagas Disease / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D018928:Immunity, Mucosal; D051379:Mice; D008807:Mice, Inbred BALB C; D015800:Protozoan Proteins / Q000008:administration & dosage / Q000276:immunology*; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014349:Trypanosoma cruzi / Q000276:immunology*; D014643:Variant Surface Glycoproteins, Trypanosoma / Q000008:administration & dosage / Q000276:immunology*
D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D014643:Variant Surface Glycoproteins, Trypanosoma; C527132:glycoprotein GP82, Trypanosoma cruzi